Canaccord Genuity Downgrades Fibrocell Science (FCSC) to Hold Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FCSC Hot Sheet
Price: $3.00 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee downgraded Fibrocell Science (NASDAQ: FCSC) from Buy to Hold with a price target of $3.00 (from $10.00).
For an analyst ratings summary and ratings history on Fibrocell Science click here. For more ratings news on Fibrocell Science click here.
Shares of Fibrocell Science closed at $2.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades PagSeguro (PAGS) to Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK312 at UBS
- Circle Internet Group (CRCL) PT Raised to $46 at Mizuho
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
